Weight-Loss Users Saw No Extra Risk, but Diabetes Users Had Higher Premature Birth Odds
The study covered more than 750,000 pregnancies, but just 529 involved possible exposure to semaglutide or liraglutide. Higher odds of premature birth appeared only among women prescribed the medicines for diabetes.
A Danish study found no statistically significant rise in the pregnancy complications examined after early exposure to semaglutide or liraglutide for weight management, offering reassurance about an increasingly pressing medical question.
The higher odds of premature birth appeared only among women prescribed the medicines for pre-existing diabetes. Researchers said diabetes itself, or related differences between patients, could explain that association.
Semaglutide, sold as Ozempic and Wegovy, and liraglutide, sold as Saxenda, belong to a group of medicines called GLP-1 receptor agonists used to treat type 2 diabetes and manage weight. Exposure can happen before someone knows they are pregnant, leaving patients and clinicians to make decisions with limited evidence.
The findings make the reason for taking the medicine central to that discussion. Combining diabetes treatment and weight management into a single category would obscure the study's most useful result: the association with premature birth differed between those groups.
Henriette Svarre Nielsen, who led the research, said the results were not enough to change current advice to stop these medicines eight weeks before a planned pregnancy. More research is needed before new counseling guidance can be established, she said.


